Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ?50%: KEYNOTE-598 3-year follow-up

Abreu, D. RodriguezReck, M.Sendur, N.Park, K.Lee, D. H.Cicin, I.Yumuk, P. F.2024-06-122024-06-1220220923-75341569-8041https://doi.org/10.1016/j.annonc.2022.02.015https://hdl.handle.net/20.500.14551/25577European Lung Cancer Congress (ELCC) -- MAR 30-APR 02, 2022 -- ELECTR NETWORK[Abstract Not Available]en10.1016/j.annonc.2022.02.015info:eu-repo/semantics/openAccess[No Keywords]Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ?50%: KEYNOTE-598 3-year follow-upConference Object33S30S31Q1WOS:000778453100007